Hormones may change how HIV prevention drug works in the body

NCT ID NCT07672717

Recruiting now Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jul 14, 2026 · Updated 4 times

Summary

This study looks at how natural hormones and hormone therapy (like birth control or gender-affirming hormones) affect the way the HIV prevention drug cabotegravir works in the body. Researchers will measure drug levels in blood, tissues, and fluids in 32 HIV-negative adults. The goal is to understand if hormones change how well the drug prevents HIV, which could help personalize prevention for people on hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabotegravir (long-acting injectable)
What this could lead to: If successful, this could help tailor HIV prevention strategies for people using hormone therapy, making PrEP more effective for diverse populations.
What could go wrong: This is an early-phase study with only 32 participants, so results may not apply broadly. It focuses on drug levels, not actual HIV prevention outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INJECTABLE PROPHYLAXIS

Contacts and locations

Locations

Johns Hopkins School of Medicine, Drug Development Unit
RECRUITING

Baltimore, Maryland, 212187, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.